Zhang Xiao-Juan, Liu Ying-Yue, Wang Hui, Hong Xiao-Yang
Department of Cardiopulmonary Bypass, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Department of PICU of Pediatric Medicine, Seventh Medical Center, PLA General Hospital, Beijing, 100000, China.
J Cardiothorac Surg. 2025 Jan 6;20(1):30. doi: 10.1186/s13019-024-03205-9.
We aimed to outline the experience with extracorporeal membrane oxygenation (ECMO) for respiratory and cardiac failure in neonates in our institution and compare our results with those from other countries.
The clinical data of 28 neonates who required ECMO assistance were studied retrospectively.
A total of 28 neonates underwent support with veno-arterial ECMO, including 14 cardiac support and 14 respiratory support. The neonates with a median age of 5 days (1-28 days) and a median weight of 3.3 kg (2.4-4.2 kg). Of these neonates, 4 were female, and 24 were male. Among the neonates. For neonates requiring ECMO support for cardiac conditions, 9 survived, resulting in a 64% survival rate. In contrast, for those requiring ECMO support for respiratory conditions, 6 survived, indicating a 42% survival rate. The survivors exhibited a significant reduction in lactic acid levels within the first 24 h. In the 15 successful weaning neonates, four neonates died at the end of the study; one was for the cardiac function failure; two were for the respiratory failure; one was given up for Bipedal necrosis; the other 11 neonates were successful discharge. Notably, two neonates underwent ECMO ventilation in the prone position without experiencing any complications.
The utilization of ECMO support in neonates experiencing severe respiratory and cardiac failure efficiently improves cardiopulmonary function and significantly reduces mortality rates among critically ill neonates. The neonates with a respiratory indication in our study have a lower survival rate than other reported in the literature. Monitoring the trend in lactate levels following ECMO support proves valuable in estimating the prognosis of affected children.
我们旨在概述我院新生儿呼吸和心力衰竭体外膜肺氧合(ECMO)的应用经验,并将我们的结果与其他国家的结果进行比较。
回顾性研究28例需要ECMO辅助的新生儿的临床资料。
共有28例新生儿接受了静脉-动脉ECMO支持,其中14例为心脏支持,14例为呼吸支持。新生儿的中位年龄为5天(1-28天),中位体重为3.3千克(2.4-4.2千克)。这些新生儿中,4例为女性,24例为男性。在需要ECMO支持治疗心脏疾病的新生儿中,9例存活,存活率为64%。相比之下,需要ECMO支持治疗呼吸疾病的新生儿中,6例存活,存活率为42%。幸存者在最初24小时内乳酸水平显著降低。在15例成功撤机的新生儿中,4例在研究结束时死亡;1例死于心功能衰竭;2例死于呼吸衰竭;1例因双下肢坏死放弃治疗;其他11例新生儿成功出院。值得注意的是,2例新生儿在俯卧位接受ECMO通气,未出现任何并发症。
在严重呼吸和心力衰竭的新生儿中使用ECMO支持可有效改善心肺功能,并显著降低危重新生儿的死亡率。我们研究中具有呼吸指征的新生儿存活率低于文献报道的其他新生儿。监测ECMO支持后乳酸水平的变化趋势对于评估患病儿童的预后很有价值。